# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-211981
Filing Date
2026-05-07
Accepted
2026-05-07 16:17:12
Documents
47
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | alec-20260331.htm iXBRL | 10-Q | 1860741
2 | EX-31.1 | alec-ex31_1.htm | EX-31.1 | 22984
3 | EX-31.2 | alec-ex31_2.htm | EX-31.2 | 22998
4 | EX-32.1 | alec-ex32_1.htm | EX-32.1 | 9835
5 | EX-32.2 | alec-ex32_2.htm | EX-32.2 | 9822
| Complete submission text file | 0001193125-26-211981.txt |  | 5624027

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | alec-20260331.xsd | EX-101.SCH | 632005
51 | EXTRACTED XBRL INSTANCE DOCUMENT | alec-20260331_htm.xml | XML | 760843

Mailing Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080 415-231-5660
Alector, Inc. (Filer) CIK: 0001653087 (see all company filings)

EIN.: 822933343 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38792 | Film No.: 26953617
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)